BMRN:NSD-BioMarin Pharmaceutical Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 79.33

Change

-0.12 (-0.15)%

Market Cap

USD 14.51B

Volume

0.92M

Average Target Price

USD 105.00 (+32.36%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

USD54.04B 16.53 12.83
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

USD27.46B N/A N/A
SGEN Seagen Inc

+2.73 (+1.89%)

USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

USD21.12B N/A N/A

ETFs Containing BMRN

Symbol Name Weight Mer Price(Change) Market Cap
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.86 (-3.91%)

USD0.01B
FXH First Trust Health Care A.. 0.00 % 0.61 %

+1.57 (+1.38%)

USD1.38B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

-2.53 (-10.14%)

USD0.07B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.58 %

+1.61 (+2.18%)

USD0.28B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

+1.67 (+2.94%)

USD0.16B
FCVT First Trust SSI Strategic.. 0.00 % 0.95 %

+0.68 (+1.35%)

USD0.28B
EASI Amplify EASI Tactical Gro.. 0.00 % 0.81 %

N/A

USD0.01B
BIOT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD8.18M
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.12 (+2.12%)

USD0.35B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.53% 39% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.53% 39% F 19% F
Trailing 12 Months  
Capital Gain -14.21% 29% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.21% 28% F 9% F
Trailing 5 Years  
Capital Gain -15.43% 48% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.43% 48% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 1.35% 36% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.35% 35% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 16.43% 98% A+ 82% B-
Risk Adjusted Return 8.24% 39% F 32% F
Market Capitalization 14.51B 97% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.56 36% F 55% F
Price/Book Ratio 3.54 62% D- 46% F
Price / Cash Flow Ratio 170.00 1% F 4% F
EV/EBITDA 157.98 6% F 7% F
Management Effectiveness  
Return on Equity 23.77% 97% A+ 92% A-
Return on Invested Capital 17.69% 92% A- 90% A-
Return on Assets -1.09% 92% A- 42% F
Debt to Equity Ratio 26.18% 38% F 55% F
Technical Ratios  
Short Ratio 8.49 17% F 7% F
Short Percent 7.05% 46% F 30% F
Beta 0.59 84% B 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.